活动性幼年特发性关节炎患儿血清Leptin、sICAM-1及TNF-α的表达变化及意义

目的观察瘦素(Leptin)、可溶性细胞间黏附分子(sICAM-1)和肿瘤坏死因子α(TNF-α)在活动性幼年特发性关节炎(JIA)患儿血清中的表达变化,并探讨其意义。方法采用ELISA法检测32例JIA患儿(JIA组)及20例健康儿童(对照组)血清中的Leptin、sICAM-1及TNF-α,用免疫散射比浊法测定血清C反应蛋白(CRP)水平,魏氏法检测两组血沉(ESR)。结果 JIA组患儿血清中Leptin、sICAM-1及TNF-α水平明显高于对照组(P均<0.05),并与ESR和CRP呈正相关(r=0.562、0.420,P均<0.05)。结论 JIA患儿血清Leptin、sICAM-1、TNF-α水平显著升高,与FSR、CRP呈正相关关系;三者可能参与了JIA的发病过程。     

氟伐他汀对充血性心力衰竭患者血清sICAM-1和sVCAM-1的影响

目的:探讨氟伐他汀短期治疗对充血性心力衰竭(CHF)患者血清中可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和肿瘤坏死因子α(TNF-α)水平的影响。方法:将97例CHF患者随机分为对照组(常规治疗组)和试药组(氟伐他汀组)。采用ELISA测定治疗前及治疗两周后血清中sICAM-1、sVCAM-1和TNF-α水平。结果:两种方法都可以明显降低血清sICAM-1、sVCAM-1和TNF-α水平(P0.05);试药组血清TNF-α水平降低更为显著(P0.05),但血清sICAM-1和sVCAM-1降低水平与对照组无显著差别。结论:在常规治疗基础上短期加用氟伐他汀治疗不能进一步降低CHF患者血清sICAM-1和sVCAM-1水平。     

妊娠期糖尿病患者血清sICAM-1、sVCAM-1和TNF-α水平检测及意义

采用ELISA法测定29例妊娠期糖尿病（GDM）患者（GDM组）及30例正常妊娠妇女（对照组）血清可溶性细胞间黏附分子-1（sICAM-1）、血管内皮细胞黏附分子-1（sVCAM-1）和肿瘤坏死因子-α（TNF—d）水平；分析其与血清空腹胰岛素（INS）、血浆葡萄糖浓度（FBG）及胰岛素抵抗的关系。结果GDM组血清TNF-α、sICAM-1、sVCAM-1均明显高于对照组IGDM组血清TNF-α水平与胰岛素敏感指数（ISI）、sICAM-1及sVCAM-1呈正相关（P均〈0．01）,GDM组血清TNF-α与sICAM-1及sVCAM-1存在协同表达作用。认为联合检测血清TNF-α、sICAM-1和sVCAM-1对控制GDM患者妊娠过程中血管内皮细胞的黏附、减少GDM发生有重要意义。     

稳心颗粒对不稳定型心绞痛病人hs-CRP、IL-6、TNF-α及sICAM-1的影响

目的研究稳心颗粒对不稳定型心绞痛(UA)病人高敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及细胞间黏附分子-1(sICAM-1)的影响。方法采用ELISA法测定48例不稳定型心绞痛病人、36例稳定型心绞痛(SA)病人和20名健康者(对照组)血清hs-CRP、IL-6、TNF-α、sICAM-1及血管细胞黏附分子-1(sVCAM-1)浓度。对UA病人予以稳心颗粒每次9g,口服,每日3次,疗程8周~12周,观察治疗前后hs-CRP、IL-6、TNF-α、sICAM-1及sVCAM-1的变化。结果UA组病人hs-CRP、IL-6、TNF-α、sICAM-1及sVCAM-1水平高于SA组(P<0.05)和对照组(P<0.01),而SA组与对照组比较无统计学意义(P>0.05)。治疗后UA病人血清hs-CRP、IL-6、TNF-α、sICAM-1及sVCAM-1水平显著降低(P<0.05)。结论UA病人体内存在着炎性反应,可能与其冠状动脉病变的不稳定性有关,稳心颗粒具有抗炎、稳定斑块等作用。     

sICAM-1、sVCAM-1在急性动脉硬化性脑梗死中的临床意义

目的:探讨可溶性细胞间黏附分子-1(sICAM-1)及可溶性血管细胞间黏附分子-1(sVCAM-1)在急性动脉硬化性脑梗死中的临床意义。方法:研究对象分为急性脑梗死组(n=60例)及对照组(n=28例),检测所有受试者血清sICAM-1、sVCAM-1水平,分析二者与脑梗死面积及临床转归之间的关系。结果:急性脑梗死患者血清sICAM-1、sVCAM-1水平显著高于对照组(P<0.01),二者与梗死面积大小呈正相关;而不同转归组之间二者含量无显著差别。结论:sICAM-1、sVCAM-1参与脑梗死炎症过程,可预示脑梗死严重程度。     

原发性胆汁性肝硬化患者血清可溶性血管细胞黏附分子-1和可溶性细胞间黏附分子-1的表达及其临床意义

目的 检测原发性胆汁性肝硬化(PBC)患者血清中可溶性血管细胞黏附分子-1(sVCAM-1)及可溶性细胞间黏附分子-1(sICAM-1)的表达,并探讨其临床意义.方法用酶联免疫吸附法(ELISA)测定27例PBC患者及20例对照组血清sVCAM-1、sICAM-1的含量,分别比较PBC患者child-pugh分级各级别上述因子表达水平.结果 PBC患者血清sVCAM-1和sICAM-1水平明显高于对照组(P<0.05);child-pugh分级B、C级患者血清sVCAM-1和sICAM-1水平高于A级(P<0.05).结论sVCAM-1、sICAM-1参与了PBC的病理生理过程,与疾病分级相关,血清8VCAM-1、sICAM-1含量增高可作为原发性胆汁性肝硬化肝损害的判断指标.     

冠心病患者炎性标志物的检测水平及意义

目的:探讨血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)和可溶性细胞间黏附分子-1(sICAM-1)在冠心病(CHD)发病机制中的意义。方法:采用酶联免疫吸附法(ELISA),检测86例CHD患者TNF-α、IL-8和sICAM-1水平,并与30例正常对照者进行比较。结果:CHD患者TNF-α、IL-8和sICAM-1水平显著高于正常对照组(P<0.01),急性心肌梗死患者和不稳定型心绞痛患者TNF-α、IL-8和sICAM-1水平显著高于稳定型心绞痛患者(P<0.01)。结论:TNF-α、IL-8和sICAM-1可能参与了CHD的发病过程,且与病变稳定性有关。     

有氧运动对急性冠脉综合征患者血清黏附分子和C反应蛋白的影响

目的: 探讨有氧运动对急性冠脉综合征(ACS)患者可溶性细胞间黏附分子-1(sICAM-1)、血管细胞黏附分子-1(sVCAM-1)和C反应蛋白(CRP)水平的影响。方法: 选取ACS患者70例,将其分为常规治疗组和有氧运动+常规治疗组（加有氧运动组）。另选健康成人为正常对照组。采用酶联免疫吸附法测定各组sICAM-1和sVCAM-1 水平,采用免疫浊度法测定CRP浓度。结果: ACS 患者循环血中sICAM-1、sVCAM-1和CRP水平明显高于正常对照组(P<0.01),两组治疗1个月后sICAM-1、sVCAM-1和CRP水平均较治疗前均明显下降(P<0.05和P<0.01)。且两组各项指标比较,加有氧运动组降低更显著(P<0.05)。结论: ACS 患者血清中sICAM-1、sVCAM-1和CRP水平明显升高,而有氧运动能明显降低ACS患者血中sICAM-1、sVCAM-1和CRP水平。     

急性冠脉综合征患者血清炎性标志物浓度变化及其临床意义

目的探讨血清炎性标志物与急性冠脉综合征(ACS)的关系。方法检测48例ACS患者血清C-反应蛋白(CRP)、可溶性血管内皮细胞黏附分子-1(sVCAM-1)和可溶性细胞间黏附分子-1(sICAM-1)等炎性因子变化,与冠脉造影结果和临床预后进行对比分析。结果1ACS组血清CRP与sICAM-1、sVCAM-1水平均高于稳定性心绞痛(SA)组和正常对照组;2sVCAM-1≥870ng/ml者3个月内主要冠脉不良事件(MACE)发生率明显高于<870ng/ml者;3血清肌钙蛋白阳性者CRP、sICAM-1、sVCAM-1浓度均明显高于阴性者;4冠脉狭窄程度在ACS组与SA组无统计学差异;冠脉狭窄程度积分与TC水平呈正相关,而与血清CRP、sICAM-1、sV-CAM-1及血浆纤维蛋白原(Fig)水平均无相关性;5sVCAM-1、Fig和肌钙蛋白预测3个月内MACE发生的敏感性分别为67.5%、82.4%、57.1%;特异性分别为54.8%、58.1%、81.5%。结论血清炎性标志物对ACS患者临床危险分层和判断预后有重要意义。     

系统性红斑狼疮患者血清可溶性黏附分子的检测

目的检测系统性红斑狼疮(SLE)患者血清黏附分子中可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性细胞间黏附分子-1(sICAM-1)的水平,并探讨其临床意义。方法采用酶联免疫吸附试验(ELISA)法,检测30名健康人和60例SLE患者血清sVCAM-1、sICAM-1水平,以分析其与SLE活动性变化关系。结果①SLE患者血清sVCAM-1平均水平为2342ng/ml,显著高于正常人对照组1240ng/ml(P<0.001)。②SLE患者中血清sICAM-1平均水平为802ng/ml,显著高于正常人对照组626ng/ml(P<0.001)。③SLE患者中,血清sVCAM-1水平活动期高于稳定期(P<0.05),sICAM-水平活动期高于稳定期(P<0.05)。④SLE组血清sVCAM-1和sICAM-1水平与SLE病情活动指数(SLEDAI)、抗dsDNA抗体水平及尿蛋白的发生呈正相关,与血清补体C3水平呈负相关。结论sVCAM-1,sICAM-1可能参与SLE发病机制。     

胃肿瘤患者循环可溶性细胞间粘附分子-1和血管细胞粘附分子-1

AIM To elucidate the biological and clinical significance of sICAM-1 and sVCAM-1 in patients with gastric cancer.METHODS The serum levels of soluble ICAM-1 and VCAM-1 were measured with sandwith enzyme immunoassay.RESULTS In gastric cancer patients, soluble ICAM-1 and VCAM-1 concentrations were significantly elevated in comparision with those of healthy subjects (289.23μg/L±32.69μg/L vs 190.44μ/L±35.92μg/L,1430.88μg/L±421.71μg/L vs 727.24μg/L±157.68μg/L, respectively, P＜0.01). The increment in serum sICAM-1 and sVCAM-1 concentrations correlated well with the staging of gastric cancer. The serum levels of sICAM-1 and sVCAM-1 in patients of Ⅲ-Ⅳ stages were higher than those of Ⅰ-Ⅱ stages (346.60μg/L±92.10μg/L vs 257.54μg/L±32.77μg/L, 1800.60μg/L±510.76μg/L vs 1262.81μg/L±236.73μg/L). The levels of sICAM-1 and sVCAM-1 were correlated significantly (r=0.49,P＜0.01). The sICAM-1 and sVCAM-1 levels correlated positively with alkaline phophatase (r=0.63,0.71,P＜0.001) and white cell count (r=0.52,0.43, P＜0.01); but correlated negatively with serum albumin (r=-0.41, -0.49, P＜0.01).CONCLUSION The measurement of circulating ICAM-1 and VCAM-1 may bring additional prognostic information for patients with gastric cancer in varying stages.INTRODUCTIONTumor growth and metastasis involves a variety of cell-cell and cell-extracellular matrix interactions mediated by cell adhesion molecules. Currently, a number of cell adhesion molecules, such as intercellular adhesion molecules-1 (ICAM-1), vascular cell adhesion molecules-1 (VCAM-1), etc. have been found.ICAM-1 and VCAM-1 are members of the immunoglobulin supergene family which are cytokine-induced glycoproteins (IL-1, TNFα and IFNγ). Both of them have five or seven extracellular immunoglobulin-like domains, a single transmembranous domain and a short cytoplasmic tail[1,2]. The natural ligand of ICAM-1 or VCAM-1 is LFA-1 (CD11a) and Mac-1 (CD11b) or VLA-4, respectively[3]. ICAM-1 is a widely distributed protein on a variety of tissues, and can be detected in many cells such as macrophage, T- and B-cells, or fibroblasts, endothelial and epithelial cells. VCAM-1 is also a widely distributed protein and is constitutively expressed on tissue macrophage, dentritic cells in lymphoid tissue and skin, as well as on bone marrow fibroblasts and epithelial cells. Expression of VCAM-1 is inducible on vascular endothelial cells under pathological conditions[4].Recently, soluble forms of several adhesion molecules including ICAM-1 and VCAM-1 were found in serum of normal donors[5]. Abnormally high levels of them have been described in some solid malignant tumors, leukemia, autoimmune disease, infectious disease, etc.The present study was carried out to measure the circulating levels of sICAM-1 and sVCAM-1 in gastric cancer before treatment was given and to study their correlation with clinical, histological and routine laboratory parameters.     

糖尿病患者血清可溶性细胞间粘附分子-1和可溶性血管细胞粘附分子-1变化的研究

目的　研究糖尿病患者血清可溶性细胞间粘附分子 - 1(s ICAM- 1)和可溶性血管细胞粘附分子 - 1(s VCAM- 1)水平的变化。方法　应用酶联免疫吸附法 (EL ISA)检测了 18例 1型糖尿病和 47例 2型糖尿病患者及 2 0例健康对照者的血清 s ICAM- 1、s VCAM- 1以及甘油三酯 (TG)水平。结果　 1血清 s ICAM- 1和 s VCAM- 1水平 ,1型、2型糖尿病患者组均显著高于健康对照组 (P<0 .0 5～ 0 .0 1) ,2型糖尿病有微血管病变组又高于无微血管病变组 (P<0 .0 5～ 0 .0 1) ,1型糖尿病与 2型糖尿病组之间无显著性差异 ;2血清 s VCAM- 1水平 ,2型糖尿病的高甘油三酯血症组 (A组 )、高甘油三酯血症合并高血压组 (B组 )高于单纯高血压组 (C组 )和甘油三酯、血压正常组 (D组 ) (P均 <0 .0 5 ) ;3 1型糖尿病和 2型糖尿病患者血清 s ICAM- 1和 s VCAM- 1之间均呈正相关关系 (r=0 .83、0 .5 3,P均 <0 .0 1)。结论　 12型糖尿病患者血清 s VCAM- 1升高与高甘油三酯血症有关 ;2血清 s ICAM- 1和 s VCAM- 1参与了糖尿病微血管病变的发病过程 ,并可作为糖尿病病情变化的监测指标     

Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction.

AIMS: Inflammatory mechanisms have been implicated in the pathogenesis of atherosclerosis. Cell adhesion molecules, expressed on endothelial cells and leukocytes, mediate transendothelial migration of leukocytes into the vessel wall, but also circulate in soluble forms. In the present study we related soluble cell adhesion molecules to the risk of suffering a cardiovascular death or a non-fatal myocardial infarction (cardiovascular death/myocardial infarction) in a substudy to the Angina Prognosis Study in Stockholm (APSIS). METHODS AND RESULTS: Soluble intercellular adhesion molecule-1, vascular adhesion molecule-1 and E-selectin were measured in serum collected on inclusion in the APSIS study. During follow-up, seven patients suffered non-fatal myocardial infarction or cardiovascular death, whereas 86 patients were event-free. Cardiovascular death/myocardial infarction was associated with elevated intercellular adhesion molecule-1 (354+/-142 vs 282+/-62ng x ml-1;P<0.01) and vascular adhesion molecule-1 (538+/-138 vs 433+/-135ng x ml-1;P =0.05), and E-selectin levels tended to be higher (72+/-54 vs 49+/-20ng x ml-1). Clinical risk factors (history of hypertension, previous myocardial infarction, diabetes and smoking) were more abundant in the event group. Subgroup analyses showed that hypertension, smoking or male sex were associated with elevated intercellular adhesion molecule-1, whereas previous myocardial infarction or male sex were associated with elevated vascular adhesion molecule-1. CONCLUSION: Patients with stable angina pectoris who developed cardiovascular death/myocardial infarction had elevated serum levels of soluble cell adhesion molecules, indicating increased inflammatory activity. The value of soluble cell adhesion molecules as prognostic markers in patients with stable ischaemic heart disease merits further study.     

冠心病可溶性细胞间黏附分子-1的检测 及其临床意义

目的　检测冠心病患者可溶性细胞间黏附分子-1(sICAM-1)的变化,探讨其在冠心病发病机理、病情监测中的意义。方法　用酶联免疫吸附法检测50例急性心肌梗死(AMI)、50例不稳定性心绞痛(UA)、30例稳定性心绞痛(SA)、30例健康者血浆sICAM-1水平。结果　AMI、UA、SA患者sICAM-1水平均较正常对照组高,且三组间差异有显著性。AMI患者按心功能分组,各组间差异亦有显著性(P均<0.05)。结论　sICAM-1可能参与了冠心病的发病过程,它可作为病情监测的指标。     

2型糖尿病肾病患者血清细胞粘附分子变化与氧化应激的关系

目的　探讨 2型糖尿病肾病患者 (DN)血清细胞粘附分子变化及其与氧化应激的关系。　方法　检测DN患者血清可溶性细胞间粘附分子 1(sICAM 1)、可溶性血管细胞粘附分子 1(sVCAM 1)、血清丙二醛 (MDA)含量和超氧化物歧化酶 (SOD)活性。　结果　早期DN及DN患者血清sVCAM 1水平〔分别为 (1 75± 0 48)、(1 91± 0 2 7)mg/L〕明显高于对照组〔(1 6 7± 0 72 )mg/L ,P <0 0 5和0 0 1〕 ,DN组明显高于单纯糖尿病 (DM)组〔(1 5 8± 0 39)mg/L ,P <0 0 5〕 ;DM组、早期DN组和DN组患者血清sICAM 1〔分别为 (75 6 0 0± 12 5 47)、(80 2 2 1± 12 4 81)、(897 6 0± 10 5 80 ) μg/L〕明显高于对照组〔(5 82 6 4± 10 2 73) μg/L ,P <0 0 0 1〕 ,其中DN组明显高于单纯DM组和早期DN组 (分别P <0 0 1和<0 0 5 ) ;单纯DM组、早期DN组和DN组患者血清SOD活性〔分别为 (86 5 9± 13 85 )、(85 6 9±11 32 )、(71 73± 16 35 )NU/L〕显著性低于对照组〔(92 73± 11 2 5 )NU/ml,P <0 0 1〕 ,MDA含量〔分别为(3 99± 1 36 )、(4 2 6± 1 95 )、(6 5 0± 2 98)nmol/ml〕显著性高于对照组〔(3 72± 0 5 7)nmol/ml,P <0 0 1〕。DM患者血清sVCAM 1与sICAM 1、收缩压、尿素氮 (BUN)和肌酐 (Cr)呈正相     

老年慢性心力衰竭患者淋巴细胞细胞间黏附分子-1、血管细胞间黏附分子-1的表达及与心功能的关系探讨

目的：探讨老年慢性心力衰竭（简称心衰）患者淋巴细胞细胞间黏附分子-1（ICAM-1）、血管细胞间黏附分子-1（VCAM-1）水平与血红蛋白（Hb）的关系及与心室重构、心功能的关系。方法对入选的76例老年慢性心衰患者（心衰组）行实验室和超声心动图检查,按 Hb水平又分为贫血组（27例）和非贫血组（49例）;并进行心功能分级。同时选择25例同期健康体检老年人为对照组,比较各组间淋巴细胞 ICAM-1、VCAM-1、Hb 、左室射血分数（LVEF）、左心室质量指数（LVMI）和平均室壁应力（MWS）。结果与对照组比较,心衰组患者 ICAM-1、VCAM-1和LVMI、MWS 明显升高,Hb 和 LVEF 降低（P ＜0．01）,随着心功能恶化,淋巴细胞 ICAM-1和 VCAM-1的水平以及 LVMI 和 MWS 逐渐升高,而 Hb 水平则逐渐降低;心衰贫血组患者淋巴细胞 ICAM-1和VCAM-1的水平以及 LVMI 和 MWS 明显高于非贫血组（P ＜0．05）;心衰患者淋巴细胞 ICAM-1和VCAM-1的水平与 LVMI 和 MWS 均呈正相关（P ＜0．01）。结论心衰患者淋巴细胞 ICAM-1和VCAM-1水平升高和 Hb 水平的降低参与了心功能不全、心室重构发生发展的病理生理过程。     

不同类型高脂蛋白血症患者血浆可溶性细胞粘附分子变化的探讨

目的 :探讨高脂蛋白血症患者血浆中可溶性细胞粘附分子 1(sICAM 1)与甘油三酯 (TG)、低密度脂蛋白胆固醇 (LDL C)、总胆固醇 (TC)、脂蛋白a(Lp a)、高密度脂蛋白胆固醇 (HDL C)的相互关系及临床意义。方法 :经体检排除心肌梗死、脑卒中、短暂性脑缺血、癌症、严重肝肾疾病的患者 16 0例 ,空腹采血。用ELISA方法测定sICAM 1,全自动生化分析仪测定血脂。结果 :①高脂蛋白血症患者血浆中sICAM I水平与TG(r =0 .15 ,P <0 .0 1)、LDL C(r =0 .16 ,P <0 .0 1)水平呈正相关 ;②高脂蛋白血症患者血浆中sICAM 1水平与HDL C(r =- 0 .15 ,P <0 .0 1)水平呈负相关。结论 :sICAM 1可能是早期动脉粥样硬化性疾病的标志 ,也可能是致病的病因基础     

细胞黏附分子-1与胆汁淤积关系研究进展

细胞黏附分子-1(intercellular adhesion molecule-1,ICAM-1)是存在于细胞膜上的一种具有多类效应的糖蛋白,可介导细胞间的趋化和黏附.ICAM-1可与肝脏内皮细胞膜表面相对应的受体结合,使内皮细胞通透性上升并分泌大量介质,促使细胞间的聚集,进而提高炎性细胞与内皮细胞间的黏附效应.近期...     

Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X)

BACKGROUND: Plasma levels of soluble vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) mediators of leukocyte adhesion to vascular endothelium may implicate in the pathogenesis of the syndrome of chest pain with normal coronary arteries. HYPOTHESIS: We attempted to determine whether markers of endothelial activation are raised in patients with chest pain and normal coronary arteries. METHODS: We measured plasma VCAM-1, ICAM-1 (ng/ ml) in 36 patients (34 men, 2 women, aged 62 +/- 9 years) with stable angina, coronary artery disease (CAD), and a positive response to exercise test; in 21 patients (6 men, 15 women, aged 56 +/- 9 years) with chest pain and normal coronary arteriograms (syndrome X); and in 11 healthy control subjects (8 men, 3 women, aged 49 +/- 14 years). RESULTS: Plasma ICAM-1 levels were significantly higher both in patients with CAD (mean +/- standard error of the mean) (328 +/- 26, p < 0.05), and in syndrome X (362 +/- 22, p < 0.01) than in controls (225 +/- 29). VCAM-1 levels were also higher in syndrome X (656 +/- 42 ng/ml) and in patients with CAD (626 +/- 42 ng/ml) than in controls (551 +/- 60, p = 0.09). CONCLUSIONS: ICAM-1 and VCAM-1 levels are increased both in patients with CAD and with syndrome X compared with control individuals. These findings may suggest the presence of chronic inflammation with involvement of the endothelium in patients with anginal chest pain and normal coronary angiograms.